Beigene, Ltd. (NASDAQ:ONC – Get Free Report) COO Xiaobin Wu sold 30,654 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $240.74, for a total transaction of $7,379,643.96. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Xiaobin Wu also recently made the following trade(s):
- On Thursday, February 20th, Xiaobin Wu sold 21,267 shares of Beigene stock. The shares were sold at an average price of $240.07, for a total transaction of $5,105,568.69.
Beigene Stock Up 3.2 %
ONC stock traded up $7.51 during trading on Thursday, hitting $244.20. 758,979 shares of the company’s stock traded hands, compared to its average volume of 354,999. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. Beigene, Ltd. has a 52 week low of $126.97 and a 52 week high of $248.16. The firm has a market cap of $23.90 billion, a price-to-earnings ratio of -29.64, a PEG ratio of 9.50 and a beta of 0.63.
Beigene Company Profile
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Featured Stories
- Five stocks we like better than Beigene
- Manufacturing Stocks Investing
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- 10 Best Airline Stocks to Buy
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.
